Akriderm SK, ointment 15 g

Acriderm SC is a combined drug for external use with anti-inflammatory, antiallergic, antiseptic, keratolytic effects.

Betamethasone dipropionate is a glucocorticosteroid with anti-inflammatory, anti-allergic, anti-exudative, anti-edema and antipruritic effect. It inhibits leukocyte accumulation, release of lysosomal enzymes and proinflammatory mediators in the inflammation focus, inhibits phagocytosis, decreases vascular and tissue permeability and prevents inflammatory edema formation.

Salicylic acid provides a keratolytic, antimicrobial action, eliminates stratum corneum and promotes deeper penetration of the glucocorticosteroid.

Indications

Topical treatment of dermatoses accompanied by hyperkeratosis: psoriasis, limited and diffuse neurodermitis, lichen planus red, eczema, dyshydrotic dermatitis, ichthyosis and ichthyoform changes.

Active ingredient

Composition

1 g of the ointment contains:

the active ingredients:

betamethasone dipropionate 0.64 mg and salicylic acid 30 mg;

excipients:

vaseline,

vaseline oil.

How to take, the dosage

Externally. Acriderm SC is applied thinly to the affected area of the skin twice a day – in the morning and in the evening.

A different frequency of application can be established by a doctor, based on the severity of the disease.

In mild cases, it is usually enough to use the ointment once a day; more frequent use may be needed for more severe lesions.

Interaction

Interaction of the drug with other medicines has not been identified.

Special Instructions

If signs of hypersensitivity or skin irritation associated with the use of the drug are noted, treatment should be discontinued and the patient should be treated with adequate therapy.

In prolonged treatment, when the drug is applied to large surfaces of the skin, when using occlusive dressings, as well as in children, systemic absorption of glucocorticosteroids is possible.

In children from 1 year old the drug is prescribed only with strict indications and under medical supervision because of possible systemic side effects associated with betamethasone. When using the drug on large surfaces and/or under occlusive dressing suppression of hypothalamic-pituitary-adrenal system function and development of hypercorticism symptoms may occur, reduction of growth hormone excretion and increase of intracranial pressure may be observed.

Atrophic changes may occur on the skin of the face more frequently than on other body surfaces after long-term treatment with topical glucocorticosteroids; the course of treatment in this case should not exceed 5 days.

Acriderm SC ointment is not intended for use in ophthalmology. Avoid contact of the drug with the eyes.

With long-term use of the drug, it should be withdrawn gradually.

Contraindications

Hypersensitivity to any of the drug components, skin tuberculosis, perioral dermatitis, pink acne (rosacea), trophic ulcers due to chronic venous insufficiency, skin tumors (skin cancer, nevus, atheroma, epithelioma, melanoma, hemangioma, xanthoma, sarcoma); dermal manifestations of syphilis, varicella, herpes simplex, skin postvaccinal reactions, open wounds, lactation, children under 1 year of age.

Side effects

When using glucocorticosteroids topically there may be: burning, irritation, dry skin, folliculitis, hypertrichosis, acne-like rashes, hypopigmentation, perioral dermatitis, allergic contact dermatitis.

Long-term use or use of occlusive dressings causes skin maceration, secondary infection, skin atrophy, sweating and purpura.

When applied to extensive body surfaces, mainly in children, systemic side effects of glucocorticosteroids and salicylates may occur.

Check with your doctor if you experience any adverse reactions not described in the instructions.

Overdose

Acute overdose is unlikely; however, with excessive or prolonged use of the drug, chronic overdose is possible, accompanied by signs of hypercorticism: hyperglycemia, glucosuria, reversible suppression of adrenal cortex function, manifestation of Cushing’s syndrome.

Treatment. Appropriate symptomatic treatment is indicated.In case of chronic toxic effects, gradual withdrawal of the drug is recommended.

.

Pregnancy use

The safety of topical use of glucocorticosteroids in pregnant women has not been established; prescription of drugs of this group during pregnancy is justified only if the potential benefit exceeds the possible risk.

The drugs in this group should not be used in high doses or for prolonged periods during pregnancy.

It is not known whether topical use of glucocorticosteroids can cause their appearance in the mother’s milk, so the question of stopping breastfeeding should be considered.

Similarities